{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Penack O"],"funding":["National Institute for Health Research (NIHR)"],"pagination":["380-386"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10920188"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["59(3)"],"pubmed_abstract":["Ruxolitinib has become the new standard of care for steroid-refractory and steroid-dependent chronic GVHD (SR-cGVHD). Our aim was to collect comparative data between ruxolitinib and extracorporeal photophoresis (ECP). We asked EBMT centers if they were willing to provide detailed information on GVHD grading, -therapy, -dosing, -response and complications for each included patient. 31 centers responded positively and we included all patients between 1/2017-7/2019 treated with ECP or ruxolitinib for moderate or severe SR-cGVHD. We identified 84 and 57 patients with ECP and ruxolitinib, respectively. We performed multivariate analyses adjusted on grading and type of SR-cGVHD (steroid dependent vs. refractory vs. intolerant to steroids). At day+180 after initiation of treatment for SR-cGVHD the odds ratio in the ruxolitinib group to achieve overall response vs. the ECP group was 1.35 (95% CI = [0.64; 2.91], p = 0.43). In line, we detected no statistically significant differences in overall survival, progression-free survival, non-relapse mortality and relapse incidence. The clinical significance is limited by the retrospective study design and the current data can't replace prospective studies on ECP in SR-cGVHD. However, the present results contribute to the accumulating evidence on ECP as an effective treatment option in SR-cGVHD."],"journal":["Bone marrow transplantation"],"pubmed_title":["ECP versus ruxolitinib in steroid-refractory chronic GVHD - a retrospective study by the EBMT transplant complications working party."],"pmcid":["PMC10920188"],"funding_grant_id":["CL-2015-09-001"],"pubmed_authors":["Wichert S","Kornblit BT","Kinsella F","Holderried TAW","Chiusolo P","Ozdogu H","Boreland W","Gavriilaki E","Daguenet E","Moiseev I","Penack O","Peric Z","Afanasyeva K","Schoemans H","Reinhardt HC","Peczynski C","Avenoso D","Piekarska A","Lemaitre J","Martinez C","Koenecke C","Mico MC","Basak GW"],"additional_accession":[]},"is_claimable":false,"name":"ECP versus ruxolitinib in steroid-refractory chronic GVHD - a retrospective study by the EBMT transplant complications working party.","description":"Ruxolitinib has become the new standard of care for steroid-refractory and steroid-dependent chronic GVHD (SR-cGVHD). Our aim was to collect comparative data between ruxolitinib and extracorporeal photophoresis (ECP). We asked EBMT centers if they were willing to provide detailed information on GVHD grading, -therapy, -dosing, -response and complications for each included patient. 31 centers responded positively and we included all patients between 1/2017-7/2019 treated with ECP or ruxolitinib for moderate or severe SR-cGVHD. We identified 84 and 57 patients with ECP and ruxolitinib, respectively. We performed multivariate analyses adjusted on grading and type of SR-cGVHD (steroid dependent vs. refractory vs. intolerant to steroids). At day+180 after initiation of treatment for SR-cGVHD the odds ratio in the ruxolitinib group to achieve overall response vs. the ECP group was 1.35 (95% CI = [0.64; 2.91], p = 0.43). In line, we detected no statistically significant differences in overall survival, progression-free survival, non-relapse mortality and relapse incidence. The clinical significance is limited by the retrospective study design and the current data can't replace prospective studies on ECP in SR-cGVHD. However, the present results contribute to the accumulating evidence on ECP as an effective treatment option in SR-cGVHD.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2026-03-15T22:56:42.418Z","creation":"2025-08-13T03:06:42.464Z"},"accession":"S-EPMC10920188","cross_references":{"pubmed":["38184740"],"doi":["10.1038/s41409-023-02174-2"]}}